M207: Ph II/III Zotrip data

By Alex Himes | Apr 13, 2017 | 3:46 PM GMT

The pivotal, double-blind, U.S. Phase II/III Zotrip trial of transdermal M207 in 565 patients with acute migraine showed that the highest dose of 3.8 mg M207 met the

Read the full 287 word article

How to gain access

Continue reading with a
two-week free trial.